WHEREAS:Registration Rights Agreement • October 7th, 2004 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
CONSULTING AGREEMENT This Agreement is made and entered into as of this 7th day of March, 2002, by and between The Quigley Corporation, a Nevada corporation (the "Company"), and Forrester Financial LLC, a New Jersey limited liability company (the...Consulting Agreement • April 11th, 2002 • Quigley Corp • Sugar & confectionery products • Pennsylvania
AGREEMENTAgreement • April 4th, 1997 • Quigley Corp • Sugar & confectionery products • Pennsylvania
AMENDED AND RESTATED WARRANT AGREEMENT -------------------------------------- This AMENDED AND RESTATED WARRANT AGREEMENT dated as of February 2, 2003 between The Quigley Corporation, a Nevada corporation (the "Company"), and Forrester Financial, LLC,...Warrant Agreement • February 18th, 2003 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
COMMON STOCK PURCHASE WARRANT PROPHASE LABS, Inc.ProPhase Labs, Inc. • January 30th, 2023 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, JXVII TRUST or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York time) on the five (5) year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from PROPHASE LABS, INC. (the “Company”), up to SEVENTY-SIX THOUSAND (76,000) shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.0005 per share (“Common Stock”). If the Termination Date is not a Business Day, then this Warrant may be exercised before 5:00 P.M. (New York time), on the next succeeding Business Day. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT (this "Agreement") is made and entered into as of the 31st day of December, 2002, (the "Effective Date") by and between THE QUIGLEY CORPORATION, a Nevada corporation ("Quigley"), and SUNCOAST...Share Exchange Agreement • February 6th, 2003 • Quigley Corp • Pharmaceutical preparations • Delaware
andRights Agreement • September 18th, 1998 • Quigley Corp • Sugar & confectionery products • Nevada
AGREEMENTAgreement • April 4th, 1997 • Quigley Corp • Sugar & confectionery products • Pennsylvania
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 7th, 2021 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 5, 2021, between ProPhase Labs, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PROPHASE LABS, INC. Common Stock ($0.0005 par value per share) Sales AgreementProPhase Labs, Inc. • December 29th, 2021 • Pharmaceutical preparations • New York
ProPhase Labs, Inc., a corporation formed under the laws of the State of Delaware (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (“ThinkEquity” or “Agent”), as follows:
TERM NOTE [GRAPHIC OMITTED]Quigley Corp • October 7th, 2004 • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 5th, 2015 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
Registration Rights Agreement (the “Agreement”), dated as of July 30, 2015, by and between PROPHASE LABS, INC., a corporation organized under the laws of Delaware, USA (the “Company”), and Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership (the “Investor”).
AGREEMENTAgreement • February 18th, 2003 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
INVESTMENT AGREEMENTInvestment Agreement • August 5th, 2015 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
INVESTMENT AGREEMENT (this “AGREEMENT”), dated as of July 30, 2015 by and between PROPHASE LABS, INC. a Delaware corporation (the “Company”), and Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership (the “Investor”).
Exhibit 10.1 ASSET PURCHASE AND SALE AGREEMENT THIS ASSET PURCHASE AND SALE AGREEMENT is made this 18th day of August, 2004, by and between JOEL, INC., a Pennsylvania corporation (hereinafter called "Seller"), and THE QUIGLEY CORPORATION, a Nevada...Asset Purchase and Sale Agreement • August 20th, 2004 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
Lebanon Co.) OPEN-END MORTGAGE AND SECURITY AGREEMENT [OBJECT OMITTED] (THIS MORTGAGE SECURES FUTURE ADVANCES) THIS OPEN-END MORTGAGE AND SECURITY AGREEMENT (this "MORTGAGE") is made as October 1, 2004, by QUIGLEY MANUFACTURING INC., a Delaware...Mortgage and Security Agreement • October 7th, 2004 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
COMMON STOCK PURCHASE WARRANT PROPHASE LABS, Inc.ProPhase Labs, Inc. • January 7th, 2021 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three (3) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from PROPHASE LABS, INC., a Delaware corporation (the “Company”), up to ____________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENT betweenUnderwriting Agreement • January 20th, 2021 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
The undersigned, ProPhase Labs, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of ProPhase Labs, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc. (hereinafter referred to as “you” (including its correlatives) or the “Representative”), and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
EXHIBIT 10.6 LICENSING AGREEMENT AND NOW, this 24TH day of AUGUST , 1996, it is hereby stipulated and agreed by and between GEORGE A. EBY III and GEORGE EBY RESEARCH (hereinafter referred to as "Licensor(s)" or "Eby"), residing at 2109 Paramount...Licensing Agreement • April 4th, 1997 • Quigley Corp • Sugar & confectionery products • Pennsylvania
EXHIBIT 10.8 AMENDMENT TO UNITED STATES EXCLUSIVE SUPPLY AGREEMENT WHEREAS, THE QUIGLEY CORPORATION, a Nevada corporation with its offices at 621 Shady Retreat Road, Doylestown, PA 18901 (hereinafter referred to as "Quigley"), and JOEL, INC., a...Agreement • February 28th, 2002 • Quigley Corp • Sugar & confectionery products
PROPHASE LABS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • September 23rd, 2020 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
ProPhase Labs, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follows:
Exhibit 10.7 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made this 1st day of October, 2004, between QUIGLEY MANUFACTURING INC., a Delaware corporation, as employer (hereinafter "Employer"), and DAVID HESS (hereinafter...Employment Agreement • October 7th, 2004 • Quigley Corp • Pharmaceutical preparations • Pennsylvania
WARRANT NO. 2015-[___] PROPHASE LABS, INC.ProPhase Labs, Inc. • December 16th, 2015 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, John E. Ligums, Jr. (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 11, 2015 (the “Issuance Date”) and on or prior to the close of business on the third anniversary of the Issuance Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from ProPhase Labs, Inc., a Delaware corporation (the “Company”), up to [ ] shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION UNITED STATES EXCLUSIVE SUPPLY AGREEMENT ---------------------------------------- This Agreement dated March 17, 1997, is made by...Exclusive Supply Agreement • September 29th, 1997 • Quigley Corp • Sugar & confectionery products
EXHIBIT 10.11 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT WHEREAS, THE QUIGLEY CORPORATION, a Nevada corporation with offices at 621 Shady Retreat Road, Doylestown, PA 18901 (hereinafter referred to as "Company"), and Eric H. Kaytes (hereinafter...Employment Agreement • February 28th, 2002 • Quigley Corp • Sugar & confectionery products • Nevada
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 19th, 2009 • Quigley Corp • Pharmaceutical preparations
This AGREEMENT is made and entered into as of August 19, 2009, between THE QUIGLEY CORPORATION, a corporation organized under the laws of the State of Nevada (the "Corporation"), and _____________________ ("Indemnitee").
STOCK PURCHASE AGREEMENTStock Purchase Agreement • June 14th, 2017 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
This STOCK PURCHASE AGREEMENT (this “Agreement”), is entered into as of June 12, 2017 by and between ProPhase Labs, Inc., a Delaware corporation (the “Company”), and The Mark S. and Donna R. Family Foundation, Inc., a Massachusetts corporation (“Seller”, and together with the Company, the “Parties” and each a “Party”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 19th, 2009 • Quigley Corp • Pharmaceutical preparations • New York
This Employment Agreement (the “Agreement”), is made as of August 19, 2009, effective as of July 15, 2009 by and between THE QUIGLEY CORPORATION, a corporation organized under the laws of the State of Delaware (the “Company”), and TED KARKUS (“Executive”).
ProPhase Labs, Inc. Amended and RestatedSeparation Agreement and General Release • June 1st, 2015 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
This Employment Agreement (the “Agreement”), is made as of May 29, 2015 (“Effective Date”) by and between ProPhase Labs, Inc. a corporation organized under the laws of the State of Nevada (“PPL” or the “Company”), and Robert V. Cuddihy, Jr. (“Executive”) and supersedes and terminates the January 1, 2015 Employment Agreement between PPL and Executive.
PROPHASE LABS, INC. OPTION AWARD AGREEMENTOption Award Agreement • March 29th, 2024 • ProPhase Labs, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT (the “Agreement”), is made effective as of the ____th day of _______ (hereinafter called the “Date of Grant”), between ProPhase Labs, Inc., a Delaware corporation (hereinafter called the “Company”), and _____________ (hereinafter called the “Participant”):
LICENSE AGREEMENTLicense Agreement • July 21st, 2022 • ProPhase Labs, Inc. • Pharmaceutical preparations • Texas
This LICENSE AGREEMENT (the “Agreement”), made and effective as of July 18, 2022 (the “Effective Date”), is by and between ProPhase BioPharma, Inc. (“ProPhase”), a corporation organized and existing under the laws of the State of Delaware, having its principal office at 711 Stewart Ave, Suite 200, Garden City, NY, 11530 and Global BioLife, Inc. (“Global BioLife” or “Licensor”), a corporation organized and existing under the laws of the State of Nevada, having its principal office at 1400 Broadfield Blvd., Suite 100, Houston, Texas 77084. Each of ProPhase and Licensor are referred to herein as a “Party” and collectively as the “Parties.”
PROPHASE LABS, INC. OPTION AWARD AGREEMENT2022 Equity Compensation Plan • March 29th, 2024 • ProPhase Labs, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT (the “Agreement”), is made effective as of the __th day of ______ (hereinafter called the “Date of Grant”), between ProPhase Labs, Inc., a Delaware corporation (hereinafter called the “Company”), and _______ (hereinafter called the “Participant”):
LEASE AGREEMENT LANDLORD: BRG OFFICE L.L.C. and UNIT 2 ASSOCIATES L.L.C., as tenants in common, TENANT: PROPHASE DIAGNOSTICS, INC.Lease Agreement • June 13th, 2022 • ProPhase Labs, Inc. • Pharmaceutical preparations • New York
This LEASE (“Lease”) is made as of the 10th day of June, 2022, by and between BRG OFFICE L.L.C. and UNIT 2 ASSOCIATES L.L.C., as tenants in common (“Landlord”), and PROPHASE DIAGNOSTICS, INC. (“Tenant”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2011 • ProPhase Labs, Inc. • Pharmaceutical preparations • Pennsylvania
This Employment Agreement (the “Agreement”), effective as of the 1st day of January, 2012, by and between ProPhase Labs, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Robert V. Cuddihy, Jr. (“Executive”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 16th, 2021 • ProPhase Labs, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of August 10, 2021, is made by and among Nebula Genomics, Inc., a Delaware corporation (the “Company”), all of the shareholders of the Company, a list of which is contained on Schedule 4.3(a) (each a “Seller Party” and collectively, the “Seller Parties”), Kamal Obbad in the capacity as Seller Party Representative, ProPhase Labs, Inc., a Delaware corporation (“Parent”), and ProPhase Precision Medicine, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Buyer”).
